Sen. Franken pleased FDA is working to address infant drug shortage
NEWS RELEASE — Washington, D.C. — U.S. Sen. Al Franken (D-Minn.) today (Wednesday, May 29) announced that the Food and Drug Administration (FDA) has taken an important first step to address a shortage of injectable drugs used primarily to treat critically ill infants.
Sen. Franken said that the FDA’s decision to allow drugs from an international manufacturer to help alleviate the shortage is important to protect infants in immediate need, but he hopes that American manufacturers will get back online as soon as possible.
“Recently, I urged the FDA to do everything in its power to end the severe shortage of products used primarily to treat critically ill infants,” said Sen. Franken. “And I’m happy to say that the critical drugs many infants need will become available in the very near future. I will continue monitoring this situation to make sure that children do not suffer because we can’t get them the medicine they need.”
The shortage was brought to Sen. Franken’s attention by heath care providers in Minnesota. On May 6, Sen. Franken sent a bipartisan letter signed by 13 of his Senate colleagues—including Sen. Amy Klobuchar (D-Minn.)—to FDA Commissioner Margaret Hamburg warning that the shortage is putting critically ill infants at risk of serious negative health outcomes.
You can read more information, including Sen. Franken’s full letter to Commissioner Hamburg, here.